TIE2 activation by antibody-clustered endogenous angiopoietin-2 prevents capillary loss and fibrosis in experimental kidney disease
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci190286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Riikka Pietilä und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Receptor, TIE-2, Angiopoietin-2, Renal Insufficiency, Chronic, Capillaries. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIDDK NIH HHS, The Knut and Alic Wallenberg Foundation.
Abstract (Originalsprache)
The role of endothelial dysfunction in tubulointerstitial fibrosis associated with chronic kidney disease (CKD) is not well understood. In this study, we demonstrate that the activation of the endothelial tyrosine kinase TIE2 alleviates renal pathology in experimental CKD in mice. TIE2 activation was achieved using a human angiopoietin-2–binding and TIE2-activating antibody (ABTAA) or through adult-induced endothelium-specific knockout of the vascular endothelial protein tyrosine phosphatase gene ( Veptp ). Both methods markedly protected CKD mice from endothelial dysfunction, peritubular capillary loss, tubular epithelial injury, and tubulointerstitial fibrosis. Conversely, silencing TIE2 through adult-induced endothelium-specific knockout of the Tie2 gene exacerbated CKD pathology. Additionally, we found that endothelial dysfunction promoted renal fibrosis not through endothelial-to-mesenchymal transition, as previously expected, but by inducing the expression of profibrotic PDGFB in tubular epithelial cells, a process that is inhibited by TIE2 activation. Our findings suggest that TIE2 activation via ABTAA warrants investigation as a therapy in human CKD, where there is a substantial unmet medical need.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
- Feinberg Cardiovascular Research Institute and Division of Nephrology and Hypertension, Northwestern University, Chicago, Illinois, USA.
- Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.
Förderung
- NEI NIH HHS
- NIDDK NIH HHS
- The Knut and Alic Wallenberg Foundation
- Novo Nordisk Foundation
- European Foundation for the Study of Diabetes
- The Swedish Kidney Foundation
- The Knut and Alice Wallenberg Foundation
- The Swedish Research Council
Zitieren
APA
Pietilä, R., Marks-Hultström, A., He, L., Nanavazadeh, S., Quaggin, S. E., Betsholtz, C., & Jeansson, M. (2025). TIE2 activation by antibody-clustered endogenous angiopoietin-2 prevents capillary loss and fibrosis in experimental kidney disease. Journal of Clinical Investigation. https://doi.org/10.1172/jci190286
Vancouver
Pietilä R, Marks-Hultström A, He L, Nanavazadeh S, Quaggin SE, Betsholtz C, et al. TIE2 activation by antibody-clustered endogenous angiopoietin-2 prevents capillary loss and fibrosis in experimental kidney disease. Journal of Clinical Investigation. 2025. doi:10.1172/jci190286
BibTeX
@article{Pietil2025,
author = {Pietilä, Riikka and Marks-Hultström, Amanda and He, Liqun and Nanavazadeh, Sami and Quaggin, Susan E and Betsholtz, Christer and Jeansson, Marie},
title = {TIE2 activation by antibody-clustered endogenous angiopoietin-2 prevents capillary loss and fibrosis in experimental kidney disease},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci190286}
}
EUVIMED